Clearmind Medicine Inc. Common Shares (CMND)
Stock · NASDAQ · Health Care
$6.26as of 10/16/2026
Price chart
Active signals
CMND Signal Track Record
How signals performed across all stocks →What CMND's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 13 | -8.0% | 31% | September 4, 2026 |
| Bollinger Band Breakout | 12 | -15.8% | 17% | October 5, 2026 |
| Volume Spike | 9 | -24.4% | 11% | September 4, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -10.3% | 17% | February 11, 2025 |
| Any 20-session window (baseline) | -8.7% | 29% |
Computed by MarketWall from daily closing prices since September 1, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CMND
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.clearmindmedicine.com/
Fundamentals
- 1-day range
- $6.24$6.5
- Market cap
- $1.78M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-544.74
- Dividend yield
- —
- Beta
- 21.21
- Avg. volume
- 63.0K
Clearmind Medicine Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- CMNDClearmind Medicine Inc. Common Shares$6.26▼ 2.49%Market cap $1.78MP/E —$5.25$3,840
- MTNBMatinas Biopharma Holdings Inc. Common Stock$2.37▼ 2.07%Market cap $1.72MP/E —$2.26$28.95
- BFRGWBullfrog AI Holdings Inc. Warrants$0.13▲ 25.85%Market cap $2.04MP/E —$0.0751$0.6488
- SXTCChina SXT Pharmaceuticals Inc. Class A Ordinary Shares$0.065▼ 5.80%Market cap $2.06MP/E —$0.0619$83,758
- AZTRAzitra Inc Common Stock$0.072▲ 0.00%Market cap $2.18MP/E 6.22$0.0518$1.09
- GNPXGenprex Inc. Common Stock$2.11▼ 7.86%Market cap $2.24MP/E —$2.53$1,210
- PPBTPurple Biotech Ltd. American Depositary Shares$1.14▼ 7.32%Market cap $2.29MP/E —$1$2.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CMND Clearmind Medicine Inc. Common Shares | $1.78M | — | $6.26 | ▼ 2.49% | $5.25$3,840 |
| MTNB Matinas Biopharma Holdings Inc. Common Stock | $1.72M | — | $2.37 | ▼ 2.07% | $2.26$28.95 |
| BFRGW Bullfrog AI Holdings Inc. Warrants | $2.04M | — | $0.13 | ▲ 25.85% | $0.0751$0.6488 |
| SXTC China SXT Pharmaceuticals Inc. Class A Ordinary Shares | $2.06M | — | $0.065 | ▼ 5.80% | $0.0619$83,758 |
| AZTR Azitra Inc Common Stock | $2.18M | 6.22 | $0.072 | ▲ 0.00% | $0.0518$1.09 |
| GNPX Genprex Inc. Common Stock | $2.24M | — | $2.11 | ▼ 7.86% | $2.53$1,210 |
| PPBT Purple Biotech Ltd. American Depositary Shares | $2.29M | — | $1.14 | ▼ 7.32% | $1$2.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platformbenzinga · 10/12/2026
- Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement DisorderYahoo · 10/8/2026
- Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating DyskinesiaBenzinga · 10/8/2026
- Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDAYahoo · 10/7/2026
- Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026Benzinga · 9/30/2026
- NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine CombinationsYahoo · 9/23/2026
- SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine CombinationsYahoo · 9/23/2026
- Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine CombinationsYahoo · 9/23/2026
- Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As PalmitoylethanolamideBenzinga · 9/23/2026
Insider Activity
Insider Actions →- HRT FINANCIAL LP · June 16, 2026 · Sale22.1K @ $3.31
- HRT FINANCIAL LP · June 15, 2026 · Sale3.2K @ $3.32
- HRT FINANCIAL LP · June 12, 2026 · Sale2.1K @ $3.36
- HRT FINANCIAL LP · June 11, 2026 · Sale225.2K @ $0.123
- HRT FINANCIAL LP · June 10, 2026 · Buy2.16M @ $0.153
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Clearmind Medicine Announces 1‑For‑8 Reverse Share Split
Clearmind Medicine Inc. has announced a 1‑for‑8 reverse share split that will take effect on October 5, 2026. The split reduces the number of shares outstanding while increasing the share price proportionally. This corporate action is a routine adjustment and does not change the company’s underlying business or financial position.
Clearmind Medicine Announces 1‑For‑8 Reverse Share Split. Clearmind Medicine Inc. has announced a 1‑for‑8 reverse share split that will take effect on October 5, 2026. The split reduces the number of shares outstanding while increasing the share price proportionally. This corporate action is a routine adjustment and does not change the company’s underlying business or financial position.